Oncopeptides submits application for conditional marketing authorization of melflufen in the EU

Pending a positive validation from the EMA, melflufen will be subject to a regulatory assessment according to the standard timelines.\n"Following Oncopeptides launch in the US, we are broadening our geographical footprint and submitting an application for conditional marketing authorization of melflufen in Europe ahead of expectations", says Marty J Duvall, Chief Executive Officer at Oncopeptides.